(Q37856554)

24 August 2017

1 reference

title

European guidelines on the clinical management of HIV-1 tropism testing (English)

1 reference

24 August 2017

0 references

K Korn

11

0 references

Maurizio Zazzi

M Zazzi

20

0 references

Vicente Soriano

V Soriano

15

0 references

Bonaventura Clotet Sala

5

B Clotet

1 reference

24 August 2017

Françoise Brun-Vézinet

4

F Brun-Vézinet

1 reference

24 August 2017

L P R Vandekerckhove

1

1 reference

24 August 2017

A M J Wensing

2

1 reference

24 August 2017

R Kaiser

3

1 reference

24 August 2017

A De Luca

6

1 reference

24 August 2017

S Dressler

7

1 reference

24 August 2017

F Garcia

8

1 reference

24 August 2017

A M Geretti

9

1 reference

24 August 2017

T Klimkait

10

1 reference

24 August 2017

B Masquelier

12

1 reference

24 August 2017

C F Perno

13

1 reference

24 August 2017

J M Schapiro

14

1 reference

24 August 2017

A Sönnerborg

16

1 reference

24 August 2017

A-M Vandamme

17

1 reference

24 August 2017

C Verhofstede

18

1 reference

24 August 2017

H Walter

19

1 reference

24 August 2017

C A B Boucher

21

1 reference

24 August 2017

European Consensus Group on clinical management of tropism testing

22

1 reference

24 August 2017

publication date

21 March 2011

1 reference

Lancet Infectious Diseases

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

394-407

1 reference

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Cell surface receptors, virus entry and tropism of primate lentiviruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

HIV and the chemokine system: 10 years later

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

A new classification for HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Structural basis for coreceptor selectivity by the HIV type 1 V3 loop

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

HIV coreceptors: role of structure, posttranslational modifications, and internalization in viral-cell fusion and as targets for entry inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Chemokine antagonists as therapeutics: focus on HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Prevalence of CCR5-tropic HIV-1 among treatment-experienced individuals in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Evaluation of diagnostic tests for infectious diseases: general principles

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Comparison of two genotypic algorithms to determine HIV-1 tropism*

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Determining human immunodeficiency virus coreceptor use in a clinical setting: degree of correlation between two phenotypic assays and a bioinformatic model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

CXCR4-using HIV type 1 variants are more commonly found in peripheral blood mononuclear cell DNA than in plasma RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Computational methods for the design of effective therapies against drug resistant HIV strains

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Comparison of human immunodeficiency virus type 1 tropism profiles in clinical samples by the Trofile and MT-2 assays

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2810%2970319-4

7 January 2021

10.1016/S1473-3099(10)70319-4

Identifiers

DOI

1 reference

24 August 2017

1 reference